Evolva receives funding from the Global Cardiovascular Innovation Center

06-Nov-2008 - USA

Evolva announced that it has received a $288,000 award from the Cleveland Clinic led Global Cardiovascular Innovation Center (GCIC). The funding is to advance the development of Evolva’s EV-077 compound series for cardiovascular disease and to explore the Formation of a dedicated cardiovascular clinical unit to be based in Cleveland, Ohio.

"We believe the collaboration with the GCIC and the Cleveland Clinic will give us great support in developing our most advanced molecule in the series (EV-077-3201-2) through the clinic, as well as to understand the indications we should select for other members of the series. To be working with such a leading cardiovascular centre is really exciting and we hope it is a relationship that will grow in the years to come." said Alexandra Santana Sorensen, Vice President Research & Development at Evolva.

According to the company, EV-077-3201-2 is a highly potent, oral, reversible inhibitor of platelet aggregation with a different mechanism of action compared to the market leading drugs in the field (such as Plavix and Aspirin). As such it has the potential to provide certain patient groups who are at risk of thrombosis with medical benefits compared to existing treatments. The compound recently completed pre-clinical testing. Other members of the EV-077 series have potential in other cardiovascular indications as well as diabetes and inflammatory disorders.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances